Clinical trials: Cardiovascular Event
Coronary Artery Bypass, Myocardial Infarction
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)
The purpose of this study is to determine whether acadesine is effective in reducing the cardiovascular and cerebrovascular adverse events in high-risk participants undergoing CABG surgery.
- Conditions
- Coronary Artery Bypass, Myocardial Infarction, Ventricular Dysfunction, Left, Stroke
- Trial name
- RED-CABG (NCT00872001)
- Testing
- Acadesine, Normal Saline
- Volunteers
- 3,080 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Bexagliflozin Efficacy and Safety Trial
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.
- Trial name
- BEST (NCT02558296)
- Testing
- Bexagliflozin
- Where
- 157 sites in United States, Canada and 8 more
- Volunteers
- 1,700 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiac Event
Minimally Invasive Cardiac Output Monitoring Device
The overall goal of this collaborative study is to advance the novel "pulse contour analysis" to the point at which it can be incorporated into a real-time device.
- Trial name
- NCT01675063
- Testing
- Retia Non-Invasive Sensors
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Michigan
Hyperlipidemia
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-HR (NCT01968954)
- Testing
- Bococizumab (PF-04950615;RN316)
- Where
- 103 sites in United States, Australia and 7 more
- Volunteers
- 711 people
- Sponsor
- Pfizer
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare…
- Trial name
- ADVANCE-2 (NCT00452530)
- Testing
- Enoxaparin, Apixaban
- Where
- 122 sites in Austria, Belgium and 25 more
- Volunteers
- 3,221 people
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Diseases, Atherosclerosis
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
- Trial name
- NCT05537571
- Testing
- SLN360
- Where
- 29 sites in Australia, Czechia and 5 more
- Volunteers
- 180 people
- Sponsor
- Silence Therapeutics plc
Acute Coronary Syndrome
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real…
- Trial name
- TRANSLATE-ACS (NCT01088503)
- Testing
- ADP receptor inhibitors
- Where
- 186 sites in United States, Puerto Rico
- Volunteers
- 12,227 people
- Sponsor
- Eli Lilly and Company
Venous Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and…
- Trial name
- ADOPT (NCT00457002)
- Testing
- Apixaban, Enoxaparin
- Where
- 296 sites in United States, Argentina and 33 more
- Volunteers
- 6,758 people
- Sponsor
- Bristol-Myers Squibb
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional…
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00527943
- Testing
- Vorapaxar
- Volunteers
- 12,944 people
- Sponsor
- Merck Sharp & Dohme LLC
Ventricular Tachycardia
INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events
This study to is being conducted in India to determine the role of catheter-based ablation for ventricular tachycardia (VT) in post- heart attack patients who meet established guidelines for implantable cardiodefibrillator (ICD)…
- Trial name
- INTERVENE (NCT02301390)
- Testing
- Amiodarone, Catheter Ablation
- Where
- 3 sites in India
- Volunteers
- 53 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Myocardial Ischemia, Acute Coronary Syndrome
Cardiac Rehabilitation for Heart Event Recovery (HER)
The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.
- Conditions
- Myocardial Ischemia, Acute Coronary Syndrome, Heart Disease, Coronary Artery Disease
- Trial name
- CR4HER (NCT01019135)
- Testing
- Cardiac Rehabilitation
- Where
- 5 sites in Canada
- Volunteers
- 169 people
- Sponsor
- University Health Network, Toronto
Carotid Artery Disease, Carotid Artery Stenosis
The Gore SCAFFOLD Clinical Study
Evaluate the safety and efficacy of the GORE® Carotid Stent for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy
- Trial name
- NCT01901874
- Testing
- Carotid Artery Stenting
- Where
- 2 sites in United States
- Volunteers
- 312 people
- Sponsor
- W.L.Gore & Associates
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Saphenous Vein Graft Disease
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous vein graft disease remains an unresolved medical problem. Many vein grafts occlude in the first year after bypass surgery, leading to adverse cardiovascular outcomes, including recurrent angina, myocardial infarction…
- Trial name
- TARGET (NCT02053909)
- Testing
- Aspirin, Ticagrelor
- Where
- 2 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Boca Raton Regional Hospital
Thrombosis, Cancer
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic…
- Conditions
- Thrombosis, Cancer, Pulmonary Embolism
- Trial name
- NCT00320255
- Testing
- Apixaban
- Where
- 14 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca